Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VOGX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Mizagliflozin | Postbariatric Hypoglycemia | Phase 2 · NCT05721729 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VOGX holds $82.1M in cash and short-term investments (as of Sep 30, 2026) and burns about $1.4M/quarter from operations, an estimated runway of 179.3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 23 · Moderate
Accordingly, management concluded that substantial doubt regarding the Company’s ability to continue as a going concern does not exist.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VOGX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | Institution (13G, 5%+) | 1,923,076 | 12.95% | 2026-08-31 |
| William Wilkison Chief Scientific Officer, Director, 10% · +155,000 options |
Insider | 1,800,000 | 12.12% | 2026-08-11 |
| James Green Chief Executive Officer, Director, 10% o · +155,000 options Includes shares also reported by William Wilkison, counted once |
Insider | 1,800,000 | 12.12% | 2026-08-11 |
| Affinity Asset Advisors, LLC | Institution (13G, 5%+) | 915,000 | 6.16% | 2026-09-30 |
| Adage Capital Management, L.P. | Institution (13G, 5%+) | 800,000 | 5.39% | 2026-09-30 |
| Steven R Delmar Chief Financial Officer, Director · +155,000 options |
Insider | 704,273 | 4.74% | 2026-08-13 |
| Richard Bentley Cheatham 10% owner |
Insider | 700,000 | 4.71% | 2026-08-11 |
| Peter Pieraccini Director · +50,000 options |
Insider | 42,735 | 0.29% | 2026-08-13 |
Share count 14,855,087 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VOGX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →